Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II study comparing neo-epitope based vaccine OSE2101 (TEDOPI) with or without anti-PD1 (Pembrolizumab) versus best supportive care as maintenance treatment in platinum-sensitive recurrent ovarian cancer patient with controlled disease after Platinum-based chemotherapy

Next Previous
X
Search
Trial Profile

Randomized Phase II study comparing neo-epitope based vaccine OSE2101 (TEDOPI) with or without anti-PD1 (Pembrolizumab) versus best supportive care as maintenance treatment in platinum-sensitive recurrent ovarian cancer patient with controlled disease after Platinum-based chemotherapy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OSE 2101 (Primary) ; Pembrolizumab (Primary)
  • Indications Carcinoma; Ovarian cancer
  • Focus Therapeutic Use
  • Acronyms TEDOVA

    • Most Recent Events

    • 19 Jan 2024 According to an OSE Immunotherapeutics media release, results of this study are expected in 2025.
    • 04 Dec 2023 Planned End Date changed from 1 Jun 2025 to 1 Dec 2025.
    • 04 Dec 2023 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top